Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case study reports the first extensively interpreted instance of dystrophic telogen effluvium potentially linked to pegylated interferon and ribavirin therapy for chronic hepatitis C, characterized through clinical and trichogram analysis.

In this report, a case of a bullous lesion developed at the injection site in a patient treated with PEG-IFN-α-2a for chronic hepatitis C was described.

This case report documents a reversible instance of complete body hair loss (alopecia universalis) in a patient undergoing chronic hepatitis C treatment with pegylated interferon alpha-2b and ribavirin, with hair regrowth observed within three months after therapy completion.

This case report identified dystrophic anagen effluvium as a previously unreported dermatological side effect of PEG-INF-α-2a/RBV combination therapy in a patient with chronic hepatitis C infection.

This case report detailed alopecia universalis developing shortly after hepatitis C treatment with peg-interferon, ribavirin, and telaprevir, suggesting potential immune-related links between interferon treatment and alopecia areata.